tiprankstipranks
Novo Nordisk (MX:NVON)
:NVON
Mexico Market
NVON
Novo Nordisk
RESEARCH TOOLSreports

Novo Nordisk (NVON) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

NVON Analyst Ratings

Hold
3Ratings
Hold
0 Buy
3 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Novo
Nordisk
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NVON Stock 12 Month Forecast

Average Price Target

$779.86
▼(-8.25% Downside)
Based on 3 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is $779.86 with a high forecast of $820.60 and a low forecast of $733.30. The average price target represents a -8.25% change from the last price of $850.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"636":"$636","951":"$951","1266":"$1,266","793.5":"$793.5","1108.5":"$1,108.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":820.60235714,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$820.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":779.8632330266665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$779.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":733.30423404,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$733.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[636,793.5,951,1108.5,1266],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,854,851.4309505492307,848.8619010984615,846.2928516476923,843.7238021969231,841.1547527461538,838.5857032953846,836.0166538446153,833.4476043938462,830.8785549430769,828.3095054923077,825.7404560415384,823.1714065907693,{"y":820.60235714,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,854,848.297171771282,842.594343542564,836.8915153138461,831.1886870851282,825.4858588564102,819.7830306276923,814.0802023989743,808.3773741702563,802.6745459415383,796.9717177128205,791.2688894841025,785.5660612553845,{"y":779.8632330266665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,854,844.7157103107693,835.4314206215385,826.1471309323077,816.8628412430769,807.5785515538462,798.2942618646154,789.0099721753846,779.7256824861538,770.4413927969231,761.1571031076923,751.8728134184615,742.5885237292307,{"y":733.30423404,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1265.362,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":881.253,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1043.132,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1059.341,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":889.931,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":866.122,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":894.82,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1015.293,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":637.199,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":651.98,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":746.13,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":764.75,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":854,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$820.60Average Price Target$779.86Lowest Price Target$733.30
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on MX:NVON
Evan Seigerman
BMO Capital
BMO Capital
$785.68
Hold
-7.57%
Downside
Reiterated
07/28/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
TD Cowen Analyst forecast on MX:NVON
Michael Nedelcovych
TD Cowen
TD Cowen
$733.3
Hold
-13.73%
Downside
Reiterated
06/29/26
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and Sanofi (NASDAQ: SNY)
Goldman Sachs Analyst forecast on MX:NVON
James Quigley
Goldman Sachs
Goldman Sachs
$715.84→$820.6
Hold
-3.46%
Downside
Reiterated
06/03/26
Goldman Sachs Sticks to Its Hold Rating for Novo Nordisk (NVO)
Argus Research Analyst forecast on MX:NVON
Jasper Hellweg
Argus Research
Argus Research
―
Hold
―
Reiterated
03/20/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Addus Homecare (NASDAQ: ADUS) and Novo Nordisk (NYSE: NVO)
Berenberg Bank Analyst forecast on MX:NVON
Kerry Holford
Berenberg Bank
Berenberg Bank
$995.2→$820.6
Buy
-3.46%
Downside
Reiterated
03/11/26
Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)
Morgan Stanley Analyst forecast on MX:NVON
Thibault Boutherin
Morgan Stanley
Morgan Stanley
$733.3→$698.38
Hold
-17.84%
Downside
Upgraded
03/03/26
Novo Nordisk (NVO) was upgraded to a Hold Rating at Morgan Stanley
Nordea Markets Analyst forecast on MX:NVON
Martin Brenoe
Nordea Markets
Nordea Markets
―
Hold
―
Downgraded
02/24/26
Novo Nordisk downgraded to Hold from Buy at NordeaNovo Nordisk downgraded to Hold from Buy at Nordea
Deutsche Bank Analyst forecast on MX:NVON
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
―
Hold
―
Downgraded
02/23/26
Novo Nordisk downgraded to Hold from Buy at Deutsche BankNovo Nordisk downgraded to Hold from Buy at Deutsche Bank
HSBC Analyst forecast on MX:NVON
Rajesh Kumar
HSBC
HSBC
$820.6→$942.82
Hold
10.92%
Upside
Reiterated
12/10/25
Novo Nordisk price target raised to $54 from $47 at HSBCNovo Nordisk price target raised to $54 from $47 at HSBC
J.P. Morgan Analyst forecast on MX:NVON
Richard Vosser
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
11/24/25
Novo selloff on Alzheimer's miss overdone, says JPMorganNovo selloff on Alzheimer's miss overdone, says JPMorgan
Bank of America Securities Analyst forecast on MX:NVON
Sachin Jain
Bank of America Securities
Bank of America Securities
$996.08
Hold
17.18%
Upside
Reiterated
10/09/25
Rothschild & Co Redburn Analyst forecast on MX:NVON
Simon Baker CFA
Rothschild & Co Redburn
Rothschild & Co Redburn
―
Buy
―
Upgraded
09/16/25
Novo Nordisk (NVO) was upgraded to a Buy Rating at Redburn Atlantic
Bernstein Analyst forecast on MX:NVON
Florent Cespedes
Bernstein
Bernstein
―
Buy
―
Upgraded
09/09/25
Novo Nordisk upgraded to Outperform from Market Perform at BernsteinNovo Nordisk upgraded to Outperform from Market Perform at Bernstein
Exane BNP Paribas Analyst forecast on MX:NVON
Peter Verdult
Exane BNP Paribas
Exane BNP Paribas
$942.82
Hold
10.92%
Upside
Upgraded
08/13/25
Novo Nordisk upgraded to Neutral from Underperform at BNP Paribas ExaneNovo Nordisk upgraded to Neutral from Underperform at BNP Paribas Exane
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on MX:NVON
Evan Seigerman
BMO Capital
BMO Capital
$785.68
Hold
-7.57%
Downside
Reiterated
07/28/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
TD Cowen Analyst forecast on MX:NVON
Michael Nedelcovych
TD Cowen
TD Cowen
$733.3
Hold
-13.73%
Downside
Reiterated
06/29/26
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and Sanofi (NASDAQ: SNY)
Goldman Sachs Analyst forecast on MX:NVON
James Quigley
Goldman Sachs
Goldman Sachs
$715.84→$820.6
Hold
-3.46%
Downside
Reiterated
06/03/26
Goldman Sachs Sticks to Its Hold Rating for Novo Nordisk (NVO)
Argus Research Analyst forecast on MX:NVON
Jasper Hellweg
Argus Research
Argus Research
―
Hold
―
Reiterated
03/20/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Addus Homecare (NASDAQ: ADUS) and Novo Nordisk (NYSE: NVO)
Berenberg Bank Analyst forecast on MX:NVON
Kerry Holford
Berenberg Bank
Berenberg Bank
$995.2→$820.6
Buy
-3.46%
Downside
Reiterated
03/11/26
Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)
Morgan Stanley Analyst forecast on MX:NVON
Thibault Boutherin
Morgan Stanley
Morgan Stanley
$733.3→$698.38
Hold
-17.84%
Downside
Upgraded
03/03/26
Novo Nordisk (NVO) was upgraded to a Hold Rating at Morgan Stanley
Nordea Markets Analyst forecast on MX:NVON
Martin Brenoe
Nordea Markets
Nordea Markets
―
Hold
―
Downgraded
02/24/26
Novo Nordisk downgraded to Hold from Buy at NordeaNovo Nordisk downgraded to Hold from Buy at Nordea
Deutsche Bank Analyst forecast on MX:NVON
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
―
Hold
―
Downgraded
02/23/26
Novo Nordisk downgraded to Hold from Buy at Deutsche BankNovo Nordisk downgraded to Hold from Buy at Deutsche Bank
HSBC Analyst forecast on MX:NVON
Rajesh Kumar
HSBC
HSBC
$820.6→$942.82
Hold
10.92%
Upside
Reiterated
12/10/25
Novo Nordisk price target raised to $54 from $47 at HSBCNovo Nordisk price target raised to $54 from $47 at HSBC
J.P. Morgan Analyst forecast on MX:NVON
Richard Vosser
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
11/24/25
Novo selloff on Alzheimer's miss overdone, says JPMorganNovo selloff on Alzheimer's miss overdone, says JPMorgan
Bank of America Securities Analyst forecast on MX:NVON
Sachin Jain
Bank of America Securities
Bank of America Securities
$996.08
Hold
17.18%
Upside
Reiterated
10/09/25
Rothschild & Co Redburn Analyst forecast on MX:NVON
Simon Baker CFA
Rothschild & Co Redburn
Rothschild & Co Redburn
―
Buy
―
Upgraded
09/16/25
Novo Nordisk (NVO) was upgraded to a Buy Rating at Redburn Atlantic
Bernstein Analyst forecast on MX:NVON
Florent Cespedes
Bernstein
Bernstein
―
Buy
―
Upgraded
09/09/25
Novo Nordisk upgraded to Outperform from Market Perform at BernsteinNovo Nordisk upgraded to Outperform from Market Perform at Bernstein
Exane BNP Paribas Analyst forecast on MX:NVON
Peter Verdult
Exane BNP Paribas
Exane BNP Paribas
$942.82
Hold
10.92%
Upside
Upgraded
08/13/25
Novo Nordisk upgraded to Neutral from Underperform at BNP Paribas ExaneNovo Nordisk upgraded to Neutral from Underperform at BNP Paribas Exane
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

3 Months
Richard VosserJ.P. Morgan
Success Rate
4/7 ratings generated profit
57%
Average Return
+0.86%
Copying Richard Vosser's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +0.86% per trade.
1 Year
Richard VosserJ.P. Morgan
Success Rate
5/7 ratings generated profit
71%
Average Return
+7.84%
Copying Richard Vosser's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +7.84% per trade.
2 Years
Richard VosserJ.P. Morgan
Success Rate
5/7 ratings generated profit
71%
Average Return
+26.59%
Copying Richard Vosser's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +26.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVON Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
6
3
1
0
0
Hold
13
12
9
6
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
15
10
6
8
In the current month, NVON has received 0 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. NVON average Analyst price target in the past 3 months is 779.86.
Each month's total comprises the sum of three months' worth of ratings.

NVON Financial Forecast

NVON Earnings Forecast

Next quarter’s earnings estimate for NVON is $13.41 with a range of $12.44 to $14.62. The previous quarter’s EPS was $18.19. NVON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.00% of the time in the same period. In the last calendar year NVON has Performed in-line its overall industry.
Next quarter’s earnings estimate for NVON is $13.41 with a range of $12.44 to $14.62. The previous quarter’s EPS was $18.19. NVON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.00% of the time in the same period. In the last calendar year NVON has Performed in-line its overall industry.

NVON Sales Forecast

Next quarter’s sales forecast for NVON is $189.91B with a range of $185.66B to $193.06B. The previous quarter’s sales results were $264.44B. NVON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 54.79% of the time in the same period. In the last calendar year NVON has Performed in-line its overall industry.
Next quarter’s sales forecast for NVON is $189.91B with a range of $185.66B to $193.06B. The previous quarter’s sales results were $264.44B. NVON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 54.79% of the time in the same period. In the last calendar year NVON has Performed in-line its overall industry.

NVON Stock Forecast FAQ

What is MX:NVON’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is 779.86.
    What is MX:NVON’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:NVON, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Novo Nordisk a Buy, Sell or Hold?
        Novo Nordisk has a consensus rating of Hold, which is based on 0 buy ratings, 3 hold ratings and 0 sell ratings.
          What is Novo Nordisk’s share price target?
          The average share price target for Novo Nordisk is 779.86. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $820.60 ,and the lowest forecast is $733.30. The average share price target represents -8.25% Decrease from the current price of $850.02.
            What do analysts say about Novo Nordisk?
            Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.
              How can I buy shares of Novo Nordisk?
              To buy shares of MX:NVON, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.